Device type · OGO
Intraocular Pressure Lowering Implant
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
OGO
Ophthalmic
Device class
Class III
FDA decisions since 2015
3
510(k), De Novo and PMA
Adverse event reports
184
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Intraocular Pressure Lowering Implant
- Product code
- OGO
- Device class
- Class III
- Review panel
- Ophthalmic
- Specialty
- Ophthalmology
- FDA record
- Classification database entry for OGO
Latest FDA decisions
P170034 · Decided Aug 10, 2018 · 284 days after receipt
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
P170043 · Decided Jun 21, 2018 · 182 days after receipt
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
P150037 · Decided Jul 29, 2016 · 282 days after receipt
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
Reports received
184
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
97
53% of reports
Injury reports
87
47% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 4 | 7 | 0 | 0 |
| Jan 24 | 5 | 11 | 0 | 0 |
| Feb 24 | 5 | 6 | 0 | 0 |
| Mar 24 | 3 | 7 | 0 | 0 |
| Apr 24 | 3 | 15 | 0 | 0 |
| May 24 | 2 | 9 | 0 | 0 |
| Jun 24 | 9 | 7 | 0 | 0 |
| Jul 24 | 8 | 6 | 0 | 0 |
| Aug 24 | 3 | 8 | 0 | 0 |
| Sep 24 | 6 | 4 | 0 | 0 |
| Oct 24 | 4 | 17 | 0 | 0 |
| Nov 24 | 2 | 7 | 0 | 0 |
| Dec 24 | 7 | 9 | 0 | 0 |
| Jan 25 | 2 | 5 | 0 | 0 |
| Feb 25 | 6 | 10 | 0 | 0 |
| Mar 25 | 4 | 18 | 0 | 0 |
| Apr 25 | 4 | 11 | 0 | 0 |
| May 25 | 1 | 4 | 0 | 0 |
| Jun 25 | 2 | 7 | 0 | 0 |
| Jul 25 | 4 | 9 | 0 | 0 |
| Aug 25 | 1 | 7 | 0 | 0 |
| Sep 25 | 3 | 9 | 0 | 0 |
| Oct 25 | 4 | 9 | 0 | 0 |
| Nov 25 | 4 | 9 | 0 | 0 |
| Dec 25 | 1 | 9 | 0 | 0 |
| Jan 26 | 1 | 3 | 0 | 0 |
| Feb 26 | 1 | 19 | 0 | 0 |
| Mar 26 | 12 | 8 | 0 | 0 |
| Apr 26 | 8 | 5 | 0 | 0 |
| May 26 | 21 | 11 | 0 | 0 |
| Jun 26 | 6 | 6 | 0 | 0 |
| Jul 26 | 14 | 4 | 0 | 0 |
| Aug 26 | 10 | 3 | 0 | 0 |
| Sep 26 | 8 | 6 | 0 | 0 |
| Oct 26 | 11 | 4 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Adverse Event Without Identified Device or Use Problem63
- Difficult to Advance48
- Separation Failure28
- Malposition of Device17
- Obstruction of Flow11
- Break9
- Migration5
- Retraction Problem5
- Device Dislodged or Dislocated4
- Contamination2
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Insufficient Information57
- No Clinical Signs, Symptoms or Conditions49
- Intraocular Pressure Increased30
- Hyphema16
- Adhesion(s)12
- Macular Edema11
- Foreign Body In Patient7
- Corneal Endothelial Cell Loss6
- Eye Injury6
- Eye Pain6
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0185-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design
Z-0186-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design
Z-0187-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design
Z-0188-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.